menu
    • menu

    Company profile for Supernus Pharmaceuticals

    NEW Drugs in Dev: 16
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc. We market our products within the United Sta...
    We are a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Over the last 30 years, we have built an extensive expertise in product development. Initially, we were a stand-alone development organization, then a U.S. subsidiary of Shire plc and, in late 2005, we became Supernus Pharmaceuticals, Inc. We market our products within the United States through our own specialty sales forces. We also seek strategic collaborations with other pharmaceutical companies to license our products outside the United States.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Supernus PharmaceuticalsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1550 East Gude Drive Rockville, MD 20850
    Telephone
    Telephone
    (301) 838-2500
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.supernus.com/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/supernus-pharmaceuticals-inc-
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Supernus Announces First Quarter 2026 Financial Results
    Supernus Announces First Quarter 2026 Financial Results

    05 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/05/3288238/19871/en/supernus-announces-first-quarter-2026-financial-results.html

    GLOBENEWSWIRE
    05 May 2026
    Share Share
    Supernus Pharma To Unveil Q1 2026 Financials, Host Conference
    Supernus Pharma To Unveil Q1 2026 Financials, Host Conference

    22 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/22/3279414/19871/en/supernus-pharmaceuticals-to-announce-first-quarter-2026-financial-results-and-host-conference-call-on-may-5-2026.html

    GLOBENEWSWIRE
    22 Apr 2026
    Share Share
    Supernus Unveils 2025 Record Q4 Financial Results
    Supernus Unveils 2025 Record Q4 Financial Results

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3244038/19871/en/Supernus-Announces-Record-Fourth-Quarter-and-Full-Year-2025-Financial-Results.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Supernus Pharma Joins March Investor Conferences
    Supernus Pharma Joins March Investor Conferences

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3243119/19871/en/Supernus-Pharmaceuticals-to-Participate-in-March-Investor-Conferences.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    Supernus to Host Q4 and FY 2025 Earnings Call on Feb. 24, 2026
    Supernus to Host Q4 and FY 2025 Earnings Call on Feb. 24, 2026

    12 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/12/3237728/19871/en/Supernus-Pharmaceuticals-to-Announce-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Host-Conference-Call-on-February-24-2026.html

    GLOBENEWSWIRE
    12 Feb 2026
    Share Share
    Lupin Introduces Topiramate Extended-Release Capsules In US
    Lupin Introduces Topiramate Extended-Release Capsules In US

    05 Feb 2026

    // PRESS RELEASE

    https://www.lupin.com/media/press-releases/lupin-launches-topiramate-extended-release-capsules-in-the-united-states

    PRESS RELEASE
    05 Feb 2026
    Share Share

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search